Visual Summaries of Randomized Controlled Trials
The RECORD trial was a prospective, randomized, open-label trial that assessed if addition of rosiglitazone to either metformin or sulfonylurea increase the rate of adverse CV outcomes as compared to the combination of metformin and…
Following the CV safety concerns with rosiglitazone especially new incidence of heart failure, the FDA mandated that all new diabetes drugs conduct studies demonstrating CV safety. SAVOR-TIMI trial sought to study the cardiovascular (CV) safety…
The TECOS trial is a multicenter, randomized, double-blind study that sought to study the cardiovascular (CV) safety of sitagliptin in patients with type 2 diabetes mellitus (DM2). It enrolled 14,671 patients with DM2 and established…
The REWIND trial aimed to assess the cardiovascular (CV) safety of dulaglutide, a glucagon-like peptide-1 (GLP-1) agonist, in patients with type 2 diabetes mellitus at higher risk for CV events. The trial involved 9,901 patients…
2009, VADT Trial: Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes, Source
CREDENCE Trial Visual Abstract In CREDENCE trial, the authors objective was to assess the effect of canagliflozin on renal outcomes in patients with type 2 DM and CKD. 4,401 patients with CKD and DM2 were…
TABLET Trial Summary: Dhillon-Smith R et al. randomized 952 women with positive testing for thyroid peroxidase antibodies and normal thyroid function and a history of miscarriage or infertility to either levothyroxine 50 μg once daily…
Primary Aldosteronism Diagnosis Algorithm Primary aldosteronism is characterized by elevated plasma aldosterone levels that leads potassium loss, hypertension secondary to sodium reabsorption and volume expansion and at times metabolic alkalosis. In order to discuss the…